Healthians posts FY26 profit as operating revenue rises 35.7% to Rs 357 crore

At-home diagnostics platform Healthians reported a Rs 5.4 crore FY26 net profit, reversing a Rs 4.77 crore loss a year earlier. Diagnostics contributed Rs 353 crore, or 99%, of operating revenue; the company says it serves 250+ cities.

— Source publishedMon, 31 Aug, 2026, 11:25 IST·First seen Mon, 31 Aug, 2026, 11:26 IST·Source Entrackr

What happened

Healthians became profitable in FY26, reporting Rs 5.4 crore net profit as operating revenue rose 35.7% to Rs 357 crore. The at-home diagnostics platform serves

Key facts

  • Revenue from operations: Rs 357 crore, up 35.7% YoY from Rs 263 crore
  • Total revenue: Rs 362 crore versus Rs 270 crore
  • Net profit: Rs 5.4 crore versus Rs 4.77 crore loss
  • Total expenditure: Rs 364 crore, up 32.4% YoY
  • Diagnostics revenue: Rs 353 crore, 99% of operating revenue
  • Employee benefits: Rs 134 crore; materials: Rs 109 crore; marketing: Rs 44 crore
  • EBITDA margin: 2.20%; ROCE: -4.86%
  • Accumulated losses: Rs 976 crore
  • Funding raised: around $75 million
  • At-home diagnostics available in 250+ cities; 10+ crore tests conducted

Why this matters

Healthians’ 250-plus-city diagnostics footprint and newly proven profitability make it a more credible partner or acquisition candidate for healthcare platforms seeking last-mile testing capacity and patient-data reach.

What to watch

  • FY27 revenue growth versus the FY26 35.7% rate.
  • Net-profit and EBITDA-margin progression, including whether profits remain positive after expansion spending.
  • Diagnostics revenue concentration, which was 99% of operating revenue, and evidence of meaningful adjacent-service monetization.
  • Order frequency, repeat-customer mix, average revenue per customer and subscription/package adoption.
  • New city additions, sample-collection route density and turnaround-time performance.
  • Customer-acquisition costs, discount intensity and competitive moves from diagnostic chains, hospital labs and digital-health platforms.
  • Corporate, insurer or employer contract wins that add recurring test volumes.
  • Prioritize expansion in adjacent tier-2 and tier-3 clusters where route density can support at-home collection economics.
  • Use newly demonstrated profitability to pursue employer wellness, insurer and corporate-health partnerships with recurring testing volumes.
  • Increase repeat-order conversion through annual screening plans, personalized test reminders and family health accounts.
  • Invest in turnaround-time reliability, quality accreditation and phlebotomist capacity to defend against price-led competitors.
  • Maintain disciplined promotional spending and disclose contribution-margin trends to demonstrate that profitability is sustainable rather than timing-driven.

Also reported by